Phase 1/2 safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): interim analysis of the CheckMate-040 dose escalation study. J Clin Oncol 34, 2016 (suppl; abstr 4012)
Refereed conference paper presented and published in conference proceedings

Full Text

Other information
All Author(s) ListEI-KHOUEIRT B Anthony, SANGRO Bruno, YAU Thomas Cheung, CROCENZI S Todd, WELLING III Theodore Hobart, YEO Winnie, CHOPRA Akhil, ANDERSON Jeffrey, DELA CRUZ Christine Marie, LANG Lixin, NEELY Jaclyn, MELERO Ignacio
Name of Conference2016 ASCO Annual Meeting, 3-7 Jun 2016, Chicago, USA
Start Date of Conference03/06/2016
Country/Region of ConferenceUnited States of America
Proceedings Title2016 ASCO Annual Meeting, 3-7 Jun 2016, Chicago, USA
Place of PublicationUnited States of America, Chicago
LanguagesEnglish-United Kingdom
Keywordsadvanced hepatocellular carcinoma ; escalation study

Last updated on 2018-22-01 at 13:24